LLY

1,147.78

-0.89%↓

JNJ

237.21

+2.66%↑

ABBV

225.83

+1.53%↑

UNH

411.66

+1.86%↑

MRK

119.88

+0.93%↑

LLY

1,147.78

-0.89%↓

JNJ

237.21

+2.66%↑

ABBV

225.83

+1.53%↑

UNH

411.66

+1.86%↑

MRK

119.88

+0.93%↑

LLY

1,147.78

-0.89%↓

JNJ

237.21

+2.66%↑

ABBV

225.83

+1.53%↑

UNH

411.66

+1.86%↑

MRK

119.88

+0.93%↑

LLY

1,147.78

-0.89%↓

JNJ

237.21

+2.66%↑

ABBV

225.83

+1.53%↑

UNH

411.66

+1.86%↑

MRK

119.88

+0.93%↑

LLY

1,147.78

-0.89%↓

JNJ

237.21

+2.66%↑

ABBV

225.83

+1.53%↑

UNH

411.66

+1.86%↑

MRK

119.88

+0.93%↑

Strona główna・Stock List・Roivant Sciences Ltd

Roivant Sciences Ltd

Open

SectorHealthcare

28.76 1.37

Buy Sell

Overview

Share price change

24h

Current

Min

28.27

Max

29.29

Key metrics
By Trading Economics
Income	669M 356M
Sales	521K 2.5M
Profit margin	14,116.825
Employees	721
EBITDA	-65M -354M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+28.22% upside

Market Stats
By TradingEconomics
Market Cap	32M 20B
Previous open	27.39
Previous close	28.76

News Sentiment

By Acuity

24%

76%

55 / 344 Ranking in Healthcare

Roivant Sciences Ltd Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

8 cze 2026, 22:20 UTC

Acquisitions, Mergers, Takeovers

Salesforce to Buy m3ter in Nod Toward AI-Native Business Models

8 cze 2026, 15:41 UTC

Major Market Movers

American Battery Shares Jump on Energy Department Victory

8 cze 2026, 23:46 UTC

Market Talk

Nikkei May Rebound After Monday's Selloff -- Market Talk

8 cze 2026, 23:37 UTC

Market Talk

Oil Edges Higher Amid Ongoing Supply Disruption Concerns -- Market Talk

8 cze 2026, 23:25 UTC

Market Talk

Should Australia Consider State-Linked Commodities Export Desk? -- Market Talk

8 cze 2026, 23:25 UTC

Market Talk

Global Equities Roundup: Market Talk

8 cze 2026, 21:57 UTC

Acquisitions, Mergers, Takeovers

Salesforce Expects to Close Deal in 2Q of Fiscal 2027

8 cze 2026, 21:56 UTC

Acquisitions, Mergers, Takeovers

Salesforce Agrees to Buy m3ter

8 cze 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

8 cze 2026, 19:22 UTC

Market Talk

Oil Settles Higher as Israel-Iran Exchanges Raise Tension -- Market Talk

8 cze 2026, 19:01 UTC

Market Talk

U.S. Natural Gas Futures Pull Back on Weather Outlook -- Market Talk

8 cze 2026, 18:52 UTC

Market Talk

Global Energy Roundup: Market Talk

8 cze 2026, 18:52 UTC

Market Talk

CAD Needs Trade Deal to Trigger Sustained Rally -- Market Talk

8 cze 2026, 18:17 UTC

Market Talk

Oil Pulls Back Further As Iran, Israel Put Strikes on Hold -- Market Talk

8 cze 2026, 17:32 UTC

Market Talk

Bank of Canada Should Incorporate Unemployment Rate Into Its Forecast -- Market Talk

8 cze 2026, 17:29 UTC

Market Talk

Crypto Market Still Stays in 'Extreme Fear' Amid Rebound -- Market Talk

8 cze 2026, 17:29 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

8 cze 2026, 16:55 UTC

Acquisitions, Mergers, Takeovers

Monte dei Paschi: Mediobanca Integration Proceeding According to Plan

8 cze 2026, 16:54 UTC

Acquisitions, Mergers, Takeovers

Monte dei Paschi to Review Proposals From Banco BPM, Intesa Sanpaolo

8 cze 2026, 16:40 UTC

Market Talk

Cryptocurrencies Rise After Iran and Israel Halt Exchanges of Fire -- Market Talk

8 cze 2026, 16:31 UTC

Market Talk

No Recession in Canada, Scotiabank's CEO Says -- Market Talk

8 cze 2026, 16:27 UTC

Market Talk

Mexican Inflation Seen Easing in May -- Market Talk

8 cze 2026, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

8 cze 2026, 16:03 UTC

Acquisitions, Mergers, Takeovers

Orange Bought Stake From Lorca

8 cze 2026, 16:01 UTC

Acquisitions, Mergers, Takeovers

Orange Completes Acquisition of Remaining 50% Stake in MasOrange

8 cze 2026, 16:01 UTC

Acquisitions, Mergers, Takeovers

Orange Acquires 100% Ownership of MasOrange

8 cze 2026, 15:58 UTC

Market Talk

Global Equities Roundup: Market Talk

8 cze 2026, 15:58 UTC

Market Talk

Gold Trims Losses After Israel, Iran Halt Exchanges of Fire -- Market Talk

8 cze 2026, 15:55 UTC

Market Talk

Markets Price Small Chance USMCA Will Be Dismantled -- Market Talk

8 cze 2026, 15:41 UTC

Market Talk

Gold Falls Below 200-Day Moving Average -- Market Talk

Peer Comparison

Price change

Roivant Sciences Ltd Forecast

Price Target

By TipRanks

28.22% upside

12 Months Forecast

Average 36.53 USD 28.22%

High 42 USD

Low 29.29 USD

Based on 9 Wall Street analysts offering 12 month price targets forRoivant Sciences Ltd - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

9 ratings

Buy

Hold

Sell

Based on 9 analysts giving stock ratings to Roivant Sciences Ltd - Dist in the past 3 months.

Sentiment

By Acuity

55 / 344 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Roivant Sciences Ltd

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It offers VTAMA, a novel topical approved for the treatment of psoriasis and in development for the treatment of atopic dermatitis; IMVT-1402 and batoclimab, which are fully human monoclonal antibodies that targets the neonatal Fc receptor in development across various IgG-mediated autoimmune indications; brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis and non-infectious uveitis, as well as for other therapies in various stages of clinical development; and Namilumab, a fully human anti-GM-CSF monoclonal antibody under Phase 2 clinical trial for the treatment of inflammatory and autoimmune diseases. The company also provides delivery platforms comprising lipid nanoparticle platform and ligand conjugate platform. It has collaboration and license agreements with Boehringer Ingelheim International, GmbH for conducting discovery work on RNA-specific adenosine deaminase 1 targeting and modulating compounds; and with Japan Tobacco Inc. for the rights to develop, register, and market tapinarof in Japan for the treatment of psoriasis and atopic dermatitis. The company was founded in 2014 and is based in London, the United Kingdom.